AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03127124
Drug: Eloxatin Injectable Product
RxNorm normalized name: Eloxatin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum.
Trial: NCT04307186
Drug: Gadoquatrane (BAY1747846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for IV injection, single dose
Trial: NCT02106468
Drug: Omega-3 soft capsules 1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
Trial: NCT04394351
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
Trial: NCT00828646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, once daily, 14 days
Trial: NCT00824317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01068327
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01068327
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02370121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
Trial: NCT00967408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitative treatment + oral inactive placebo for 6 months
Trial: NCT02483247
Drug: BBI503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
Trial: NCT02483247
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m\^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
Trial: NCT02483247
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m\^2 body surface area is administered intravenously once every three weeks (21-days).
Trial: NCT00647712
Drug: Depakote ER® Tablets 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg, single dose fasting
Trial: NCT02738775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02683759
Drug: 5-Aminosalicyclic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage is as instructed by patient's physician
Trial: NCT04745143
Drug: Placebo Cap
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo as a comparator
Trial: NCT03228238
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin calcium 10mg
Trial: NCT03228238
Drug: Standard medication for variant angina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Channel blocker or NG
Trial: NCT01018264
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
Trial: NCT02503605
Drug: Biosimilar recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
Trial: NCT02503605
Drug: Urinary FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian stimulation with 150 IU/day urinary FSH
Trial: NCT03063541
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg daily as one tablet
Trial: NCT00367263
Drug: Alvesco (Ciclesonide) 160 ug/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002884
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04441450
Drug: [14C]ICP-022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg suspension containing 100μCi of \[14C\]ICP-022
Trial: NCT02316197
Drug: MSC2490484A (M3814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
Trial: NCT01859715
Drug: Hydrocodone
RxNorm normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
Trial: NCT00945919
Drug: Oxymorphone ER
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid Opioid rotation/titration
Trial: NCT00128180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01251484
Drug: BIBF1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet 200 mg twice daily until progression
Trial: NCT05337878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelacarsen-matching placebo administered by SC injection.
Trial: NCT01584947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge taken three times a day for two weeks
Trial: NCT02644967
Drug: IMO-2125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
Trial: NCT00782652
Drug: inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
Trial: NCT00673452
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
Trial: NCT03069027
Drug: saline adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03069027
Drug: Xylocaine, adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03717038
Drug: Sym004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
Trial: NCT01800071
Drug: MVA-EBNA1/LMP2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02287415
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00265811
Drug: Folfox
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00018356
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02928328
Drug: Pain modulation
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
Trial: NCT02969928
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Clarithromycin 500mg bid for 7 days
Trial: NCT02404363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --\> placebo 150 mg/d x 7days then 75mg/d
Trial: NCT03609294
Drug: Treatment A (Fimasartan, Linagliptin)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of Fimasartan and Linagliptin
Trial: NCT01132521
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
Trial: NCT02258152
Drug: SYN120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
Trial: NCT02258152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo QD
Trial: NCT02629146
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02629146
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02537080
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
Trial: NCT04485481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching single dose placebo
Trial: NCT04485481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching multiple dose placebo
Trial: NCT02100267
Drug: Methacholine Chloride (SK-1211)
RxNorm normalized name: Methacholine Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
Trial: NCT01479634
Drug: Standard ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
Trial: NCT01479634
Drug: Study-Provided ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study provided drugs:~1. Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]) PLUS~2. Efavirenz \[EFV\]
Trial: NCT00402389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four capsules will be taken daily for 8 weeks.
Trial: NCT00211081
Drug: Spironolactone (drug)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
Trial: NCT01788501
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
Trial: NCT01503489
Drug: Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
Trial: NCT02772016
Drug: Colla corii asini
RxNorm normalized name: CORID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of Colla corii asini in powder form daily for 4 weeks
Trial: NCT00956150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo TID PO x 10 days
Trial: NCT00678691
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01689896
Drug: Testosterone Gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01689896
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03192150
Drug: ISV-305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone in DuraSite® 2 twice daily for 16 days
Trial: NCT00219934
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART therapy
Trial: NCT03623737
Drug: neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection
Trial: NCT01890200
Drug: TCM-700C
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An add-on drug to conventional treatment of Hepatitis C
Trial: NCT01890200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, without acting ingredient.
Trial: NCT01142258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive or inert pill which will be used as a comparator
Trial: NCT01485861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally once daily
Trial: NCT01485861
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally bid
Trial: NCT02665728
Drug: BLI400 Laxative
RxNorm normalized name: LAXATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00705575
Drug: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
Trial: NCT01611571
Drug: placebo Risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly placebo of Risedronic Acid
Trial: NCT03296163
Drug: EU-approved Avastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg IV every 3 weeks on Day 1
Trial: NCT04055194
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
Trial: NCT00354224
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03844451
Drug: Bupivacaine and Epinephrine
RxNorm normalized name: Bupivacaine and epinephrine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
Trial: NCT00702130
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pravastatin 40mg per os once daily
Trial: NCT00079274
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00079274
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00079274
Drug: Locally Directed Therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
Trial: NCT00226616
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01683292
Drug: Inhaled VR040
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01683292
Drug: Placebo for VR040
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm
Trial: NCT00843154
Drug: Standard chronic heart disease therapy
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
Trial: NCT02187315
Drug: induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03056690
Drug: ASP0819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT03056690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT01585766
Drug: MEDI-551 60 MG-SC
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received SC injection of 60 mg MEDI-551 on Day 1.
Trial: NCT01585766
Drug: PLACEBO-IV-SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
Trial: NCT01585766
Drug: MEDI-551 300 MG-SC
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received SC injection of 300 mg MEDI-551 on Day 1.
Trial: NCT01502644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching oxycodone, placebo-matching morphine
Trial: NCT00203450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill
Trial: NCT02690961
Drug: Kukoamine B Mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Trial: NCT02690961
Drug: placebo multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01701258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose placebo capsule during the fMRI session only
Trial: NCT00177424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets
Trial: NCT02733380
Drug: Liposomal Doxorubicin or mitoxantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles
Trial: NCT00706862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, twice per day
Trial: NCT02000765
Drug: GSK2140944 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing \[14C\] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
Trial: NCT02000765
Drug: GSK2140944 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing \[14C\] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
Trial: NCT00759525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for fourteen days
Trial: NCT01778920
Drug: EC17 imaging contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
Trial: NCT00605891
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
Trial: NCT04070495
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
Trial: NCT02182271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01252524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet po TID before each meal with 8 oz of water for 6 months
Trial: NCT01482104
Drug: MAL-PDT re-treatment
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
Trial: NCT01482104
Drug: usual MAL-PDT
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
Trial: NCT02948842
Drug: Clostridium Histolyticum Collagenase
RxNorm normalized name: Clostridium histolyticum collagenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.